1. Introduction {#sec1-jcm-08-02081}
===============

Vulvar cancer is a rare malignancy, accounting for 4% of all gynecological cancers; 65% of these cases occur in developed countries \[[@B1-jcm-08-02081]\]. Historically, vulvar cancer was most commonly observed at a median age of 65--70 years \[[@B2-jcm-08-02081]\]. The incidence of vulvar cancer in Japan is one-tenth to one-sixth of that in Western countries \[[@B2-jcm-08-02081]\]. According to a systematic review \[[@B3-jcm-08-02081]\], the pooled five-year overall survival (OS) rate is 64.9%, and patients with International Federation of Gynecology and Obstetrics (FIGO) stage I, II, III, and IV disease have five-year OS rates of 84.0%, 74.6%, 47.8%, and 9.4%, respectively. Vulvar cancer incidence rates have increased worldwide \[[@B4-jcm-08-02081],[@B5-jcm-08-02081],[@B6-jcm-08-02081],[@B7-jcm-08-02081]\], and the incidence has increased with age \[[@B7-jcm-08-02081]\].

The population in Japan has been significantly and steadily aging. In 2017, 27.7% of Japanese was 65 years old or older, and 13.8% was 75 years old or older \[[@B3-jcm-08-02081]\]. In general, aging is a risk factor for gynecological cancer, and elderly patients often undergo suboptimal treatment, particularly for surgery, resulting in compromised survival. Because vulvar cancer is more common in elderly patients \[[@B8-jcm-08-02081]\], the demographics of vulvar cancer in Japan are likely to change with time.

Vulvar cancer has been relatively understudied worldwide, including in Japan, with no large-scale clinicopathological investigations of vulvar cancer in the past three decades. Moreover, the published studies examined small samples, which interfered with data interpretation and utilization \[[@B9-jcm-08-02081]\]. Therefore, large-scale studies are needed to understand the demographics and recent trends of vulvar cancer in Japan. Such findings may help establish optimal treatment strategies. The objective of this study was to examine populational trends in clinicopathological characteristics of vulvar cancer in Japan.

2. Materials and Methods {#sec2-jcm-08-02081}
========================

2.1. Study Sites {#sec2dot1-jcm-08-02081}
----------------

The study protocol was approved by the Ethics Committee of Kurume University (protocol number: 14034), which served as the host institution, and each participating Japanese Gynecologic Oncology Group (JGOG)-affiliated institution reviewed the protocol and approved the study. The study protocol was registered at the University Hospital Medical Information Network (UMIN) (protocol number: UMIN-000017080). The study concept and participation call were initially announced at all JGOG-designated institutions (181 sites), and 109 (60.2%) sites voluntary participated in the study. The study sites, however, covered all high-volume centers in Japan.

2.2. Data Collection {#sec2dot2-jcm-08-02081}
--------------------

Upon completion of data collection by participating clinicians, the anonymous de-identified data sheets were transferred to the host institution. Data were then compiled into a master Excel data sheet by the research staff. The principal investigators reviewed the accuracy, consistency, and quality of the dataset, and when there was disagreement in a data element, the principal investigator and investigators at each participating institution discussed the context to achieve adjudication.

2.3. Patient Eligibility {#sec2dot3-jcm-08-02081}
------------------------

Consecutive patients with invasive vulvar cancer from January 2001 to December 2010 were examined, and data curation of this retrospective observational study was conducted from August 2014 to March 2016. JGOG institutions are thought to see more patients with vulvar cancer, estimated at 5--10 patients per institution annually for 10 years. The inclusion criteria were a diagnosis of and treatment for invasive vulvar cancer, including patients whose initial therapy had a palliative intent and patients with primary vulvar cancer, including all histological types. Patients with malignant melanoma were excluded from the analysis. For eligible patients, information on patient demographics, tumor characteristics, surgical treatment, radiotherapy, chemotherapy, and survival outcomes was obtained from archived medical records.

2.4. Clinical Information {#sec2dot4-jcm-08-02081}
-------------------------

Patient demographics included age and year of diagnosis. Tumor characteristics included histological type (squamous, adenocarcinoma, or others), cancer stage, tumor size (2 cm increments), and surgical margin status (involved, \<1, 1--2, or \>2 cm). Surgical treatment included type of vulvar surgery (simple vulvectomy, partial radical vulvectomy, or radical vulvectomy), details of inguino-femoral lymphadenectomy (laterality, extent as resection versus dissection, unilateral/bilateral deep lymphadenectomy, number of harvested and tumor-involved nodes, and use of sentinel lymphadenectomy), and reconstructive surgery (partial skin graft, cutaneous flap, or myocutaneous flap). Information on perioperative complications was abstracted (wound dehiscence, edema, infectious lymphangitis, thrombosis, frequency, and grade of urinary tract infection).

Radiotherapy information included use in a neoadjuvant, adjuvant, definitive, or palliative setting. The details of radiotherapy were also abstracted, including radiation field, irradiation method (radical or palliative irradiation), linear accelerator (LINAC), electron beam, total dose, and treatment duration. Radiotherapy-related toxicity (both early and late) was also documented. Details on regimens and cycles of chemotherapy were obtained for patients who received concurrent chemoradiotherapy. Chemotherapy information included the setting (neoadjuvant, adjuvant, or salvage), regimen type, administered cycles, and treatment-related toxicity. Survival information included follow-up time, presence of recurrent/progressive disease, and vital status (death from vulvar cancer, death from other causes, or alive).

2.5. Study Definitions {#sec2dot5-jcm-08-02081}
----------------------

Patients were grouped by age as non-older (\<60 years), young-older (60--79 years), and oldest-old (≥80 years) per the World Health Organization/United Nations criteria (5). Cancer stage was reassigned based on the 2008 International Federation of Gynecology and Obstetrics (FIGO) criteria \[[@B6-jcm-08-02081]\]. Progression-free survival (PFS) was defined as the time interval between vulvar cancer diagnosis and the first recurrence/progression of disease or death from vulvar cancer. Cause-specific survival (CSS) was defined as the time interval between vulvar cancer diagnosis and death from vulvar cancer. Overall survival (OS) was defined as the time interval between vulvar cancer diagnosis and death from any cause. Data on patients without survival events at the last follow-up visit were censored.

2.6. Study Aims {#sec2dot6-jcm-08-02081}
---------------

The primary objective of this study was to outline the time-specific descriptive statistics of the clinicopathological features of invasive vulvar cancer in Japan. The secondary objective was to assess the temporal trends of survival statistics and the prognostic factors of invasive vulvar cancer in the study population.

2.7. Statistical Considerations {#sec2dot7-jcm-08-02081}
-------------------------------

Standard statistical methods were used to describe continuous variables as mean (±SD) or median Interquartile range (IQR) values based on normality, as assessed using the Kolmogorov--Smirnov test. Significance in differences among multiple groups (more than two) was assessed using one-way ANOVA or the Kruskal--Wallis *H* test, as appropriate. Discrete and categorical variables are displayed with numbers and percentages per group, and the statistical significance of differences was assessed with chi-squared tests.

For cohort-level analysis, the Joinpoint trend analysis software (version 4.4.0.0, National Cancer Institute, Bethesda, MD, USA) was used to examine temporal trends over time. Single calendar years were used as time increments, and percent frequencies with confidence intervals (CI) or observed values of 5-year survival rates with standard errors are reported. The 5-year survival time point was based on the median follow-up of the study cohort. Linear segmented regression was used to analyze temporal trends, and log-transformation was performed to determine annual percentage rate changes (APC) of the slope with 95% CI. Relative changes in outcomes were based on the modeled value in this study.

For the patient-level analysis, Cox proportional hazard regression models were fitted to assess the prognostic impact of the clinicopathological factors of interest on survival, and the magnitude of statistical significance was expressed using hazard ratio (HR) and 95% CI. Specifically, on the basis of the results of the cohort-level analysis, we examined the association of patient age and survival adjusted with a priori survival factors, histology, stage, tumor size, and treatment types. The year of diagnosis was also considered in the model. This parsimonious approach was due to the relatively small sample size of our study.

To examine if the cohort-level characteristics observed in the study population are unique to Japanese women, the National Cancer Institution's Surveillance, Epidemiology, and End Result (SEER) Program was used for external validation (US cohort). Briefly, the SEER database is the largest population-based tumor registry in the United States, covering approximately 34.6% of the population in the latest version \[[@B10-jcm-08-02081]\]. The cohort-level analysis was carried out to examine temporal trends in age, stage, and survival rates over time, as described earlier.

Various sensitivity analyses were performed to examine the robustness of the analysis, and trends and outcomes were assessed for stage I disease, surgery, and squamous histology. These subgroups were chosen on the basis of the rationale that vulvar cancer is more likely to exhibit squamous histology in early-stage disease, and surgical treatment remains the mainstay of treatment. In the statistical analysis, *p* \< 0.05 was considered to indicate statistical significance (two-tailed hypothesis). The Statistical Package for Social Sciences (version 24.0, Armonk, NY, USA) was used for all analyses.

3. Results {#sec3-jcm-08-02081}
==========

3.1. Patient Characteristics {#sec3dot1-jcm-08-02081}
----------------------------

There were 1061 women who met the inclusion criteria ([Table 1](#jcm-08-02081-t001){ref-type="table"}). The median number of vulvar cancer cases per site was 9.5 (IQR 5--14). The median age was 72 years, with 257 (24.2%) oldest-old patients. The tumors were more likely to be squamous (*n* = 768, 72.4%) and in stage I (*n* = 397, 37.4%). Metastatic tumors to inguino-femoral lymph nodes or distant organs were seen in 312 (29.4%) women. Most patients underwent surgical treatment (*n* = 800, 75.4%).

Regarding the surgical treatment, 273 (34.1%) patients underwent radical vulvectomy, 259 (32.4%) underwent some type of reconstructive surgery, and 494 (61.8%) underwent inguino-femoral lymphadenectomy. Tumors with close or involved surgical margins accounted for 436 (54.5%) cases. Perioperative complications were relatively infrequent (*n* = 100, 12.5%). Radiotherapy with any indication was performed in 410 (38.6%) women, with definitive (*n* = 194, 18.3%) and adjuvant (*n* = 168, 15.8%) radiotherapy being the two most common indications. Among women who received radiotherapy, concurrent chemotherapy was used in 103 patients (25.1%).

3.2. Demographics Trends {#sec3dot2-jcm-08-02081}
------------------------

The number of oldest-old women significantly increased from 18.0% to 30.6% (70.5% relative increase), whereas the number of young-older women decreased from 64.0% to 48.8% (23.7% relative decrease) (for both, *p* \< 0.05; [Figure 1](#jcm-08-02081-f001){ref-type="fig"}A). There was no change in histology type ([Figure 1](#jcm-08-02081-f001){ref-type="fig"}B). A stage shift was observed, and cases of stage I disease decreased from 43.0% to 34.0% (21.0% relative decrease), whereas cases of tumors with inguino-femoral nodal or distant metastasis increased from 23.2% to 35.6% (53.3% relative increase) (for both, *p* \< 0.05; [Figure 1](#jcm-08-02081-f001){ref-type="fig"}C). The number of women who underwent surgical treatment decreased from 84.0% to 69.7% (17.0% relative decrease), whereas utilization of radiotherapy increased from 34.4% to 43.2% (25.7% relative increase) (*p* \< 0.05; [Figure 1](#jcm-08-02081-f001){ref-type="fig"}D).

3.3. Cohort-Level Survival Trends {#sec3dot3-jcm-08-02081}
---------------------------------

The median follow-up of censored cases was 58.2 months (IQR, 23.6--86.2), with 423 cases of recurrence or progressive disease, 280 deaths from vulvar cancer, and 349 deaths from any cause during the follow-up. Among those who died, the median time to death was 14.5 months (IQR 7.2--37.8). Five-year survival rates significantly decreased ([Figure 2](#jcm-08-02081-f002){ref-type="fig"}A): 66.9% to 51.0% for PFS (23.7% relative decrease, APC −3.0, 95% CI −5.0 to −0.9, *p* = 0.012), 79.5% to 67.9% for CSS (14.6% relative decrease, APC −1.7, 95% CI −3.2 to −0.2, *p* = 0.029), and 74.9% to 62.3% for OS (16.9% relative decrease, APC −2.0, 95% CI −4.0 to −0.1, *p* = 0.045).

3.4. Patient-Level Survival Analysis {#sec3dot4-jcm-08-02081}
------------------------------------

Patient demographics per age group are shown in [Table 2](#jcm-08-02081-t002){ref-type="table"}. Oldest-old women were more likely to have squamous tumors (81.7% versus 66.2--70.6%) and close/involved surgical margins (75.3% versus 60.3--66.0%), but less likely to undergo surgical treatment (56.0% versus 77.7--91.9%), particularly radical vulvectomy (15.3% versus 37.4--38.9%), vulvar reconstruction (21.5% versus 34.4--36.0%), and inguino-femoral lymphadenectomy (43.8% versus 65.3--66.6%) than younger women (for all, *p* \< 0.05). Oldest-old women were more likely to receive radiotherapy (46.1% versus 33.6--37.8%) and less likely to receive concurrent chemotherapy during radiotherapy (6.8% versus 28.3--45.2%) or systemic chemotherapy (4.7% versus 16.0--21.2%) than younger women (all, *p* \< 0.05).

Similar trends were also observed for stage I disease only ([Table 3](#jcm-08-02081-t003){ref-type="table"}). Despite the similar tumor stage and size across the age groups, women in the oldest-old group were less likely to receive optimal surgery-based treatments than women in the younger groups. On multivariable analysis ([Table 4](#jcm-08-02081-t004){ref-type="table"}), oldest-old women had an approximately 60% higher risk of recurrence/progression of vulvar cancer (adjusted HR 1.586, 95% CI 1.139--2.209) and a roughly two-fold higher risk of all-cause mortality (adjusted HR 2.172, 95% CI 1.509--3.126) than non-older women (for all, *p* \< 0.05). This association was also observed in subgroups with squamous tumors, stage I diseases, and surgery ([Table 4](#jcm-08-02081-t004){ref-type="table"}).

3.5. External Validation Cohort {#sec3dot5-jcm-08-02081}
-------------------------------

In the US cohort (*n* = 10,154), the median age was 68 years (IQR 54--80), with 26.4% being oldest-old (*n* = 2683). The number of oldest-old women did not change from 2001 to 2010 (25.2% to 27.8%, APC 1.1, 95% CI −0.5 to 2.8, *p* = 0.160; [Supplemental Figure S1A](#app1-jcm-08-02081){ref-type="app"}). The distribution of tumor stages was also unchanged during the study period ([Supplemental Figure S1B](#app1-jcm-08-02081){ref-type="app"}).

The median follow-up of censored cases was 104 months (IQR 78--139), and during follow-up, there were 2046 deaths from vulvar cancer and 5433 deaths from any cause. Among those who died, the median time to death was 27 months (IQR, 10--62). The five-year CSS rate remained unchanged during the study period (81.8% to 79.9%, APC −0.3, 95% CI −0.6 to 1.0, *p* = 0.132; [Supplemental Figure S1C](#app1-jcm-08-02081){ref-type="app"}). There was a slight decrease in the five-year OS rate from 62.7% to 58.5% (6.7% relative decrease, APC −0.8, 95% CI −1.4 to −0.1, *p* = 0.027).

When the two cohorts were compared ([Figure 2](#jcm-08-02081-f002){ref-type="fig"}B), the proportion of oldest-old in the Japan cohort was lower than that in the US cohort at the beginning of the study (18.0% versus 25.2%) but became higher at the end of the study period (30.6% versus 27.8%). In 2001, the five-year CSS rates were similar in the two cohorts (Japan versus US cohort: 79.5% versus 81.8%); in 2010, the five-year CSS rates in the Japan cohort and US cohort were 67.9% and 79.9%, respectively.

4. Discussion {#sec4-jcm-08-02081}
=============

Key findings of this study include that women with vulvar cancer in Japan have become significantly older and that tumors are more likely to metastasize outside the vulva. Accordingly, the survival of women with vulvar cancer in Japan has significantly decreased. Several points deserve further discussions.

First, women with vulvar cancer in our study population were significantly aging, thus reflecting the extremely aging population trend in Japan \[[@B11-jcm-08-02081]\]. In Western countries, the number of women with vulvar cancer has increased, but the number of oldest-old has not changed \[[@B12-jcm-08-02081],[@B13-jcm-08-02081],[@B14-jcm-08-02081]\]. This trend was also observed in the US validation cohort, making our finding unique. Generally, elderly patients are less likely to receive radical treatment due to their fragility or medical comorbidities \[[@B8-jcm-08-02081]\], as we also observed in our study; in fact, oldest-old women with stage I disease were more likely to receive non-surgical treatment. Among those who underwent surgery, oldest-old women were less likely to receive radical surgery, presenting less adequate surgical resection margin. Collectively, our study clearly demonstrates the impact of aging in cancer management. As the global population ages, awareness of this phenomenon is necessary among care providers \[[@B15-jcm-08-02081]\].

The second point is the stage shift to more advanced disease in Japan. No stage shift was particularly found in studies conducted in Western countries, including in our US validation cohort \[[@B12-jcm-08-02081],[@B13-jcm-08-02081],[@B14-jcm-08-02081]\]. While we do not know the exact cause of this association, plausible explanations can be hypothesized. First, physiologically, aging is associated with immunosenescence, which may escalate tumor spread in elderly patients \[[@B16-jcm-08-02081]\]. Second, patient compliance may affect the timing of seeking care for treatment. For instance, elderly women are less likely to have a breast cancer screening than younger women, resulting in delayed diagnosis \[[@B17-jcm-08-02081]\]. In addition, delayed diagnosis is common for vulvar cancer and negatively impacts survival. Furthermore, proactive diagnostic intervention and biopsy may be necessary for a suspected vulvar mass and lesion. Society- and community-based efforts may help improve the awareness of early signs and symptoms of vulvar cancer for both care providers and patients.

The third point involves the decreased cohort-level survival, which may be associated with the increase in the oldest-old population and the stage shift to advanced disease; these two latter phenomena likely contributed the decreased five-year survival rates additively and synergistically. In Western studies \[[@B12-jcm-08-02081],[@B13-jcm-08-02081],[@B14-jcm-08-02081]\], no changes in vulvar cancer mortality were observed in the US validation cohort. In our study, nearly 80% (280/349) of deaths were due to vulvar cancer; this is higher than what observed in the US cohort (37.7%; 2046/5433). This adds new information to the literature, in that Japanese women with vulvar cancer are more likely to die from vulvar cancer than from other causes; this is likely because it is commonly thought that vulvar cancer is a disease of the elderly and that older women are likely to die from other causes. Nationwide efforts may be needed to improve the survival of women with vulvar cancer in Japan.

Finally, the effects of hospital experience and surgical volume on vulvar cancer management merit discussion. In our study, the annual median number of vulvar cancer cases at each institution was 9.5 (less than one per year per institution). As the incidence of vulvar cancer in Japan was lower than that in Western countries \[[@B2-jcm-08-02081]\], this may simply lead to lack of experience, particularly for surgery. The current study findings support that surgical performance in Japan seems inferior to European quality.

For instance, the number of surgically treated women who underwent incomplete tumor resection in our study, evidenced by the presence of tumors in the surgical margin, was significantly higher than that reported in a recent European study (22.4% versus 9.9%) \[[@B18-jcm-08-02081]\], in which the number of patients per hospital was significantly greater than that in our study: 1618 cases per 29 institutions over 10 years (5.5 versus 0.95 cases per institution per year) \[[@B18-jcm-08-02081]\], implying that surgical volume affects surgical performance in vulvar cancer.

As high surgical volume is clearly associated with improved survival in other gynecologic cancer types, centralization of hospitals treating vulvar cancer may be necessary in Japan \[[@B19-jcm-08-02081],[@B20-jcm-08-02081],[@B21-jcm-08-02081],[@B22-jcm-08-02081]\]. Other considerations may include demographic changes, community-based education and campaigns regarding vulvar cancer signs/symptoms, a prompt referral system to treating center, and establishment of a credentialing system for oncology centers and surgeons.

The strengths of our study include the large sample size and an external US validation cohort that showed clear contrasts. To our knowledge, vulvar cancer reports in Japan were available only for local specific geographic areas, with no national surveys \[[@B9-jcm-08-02081],[@B11-jcm-08-02081]\]. We believe that our study is the first study to demonstrate nationwide trends in vulvar cancer in Japan. The detailed treatment information collected for this study enriched the quality of the analysis.

Nonetheless, our study has several limitations. First, the study has all the limitations inherent in a retrospective study. A salient unmeasured bias that can impact the outcomes includes medical comorbidity, frailty, performance status, surgeon's experience, patient compliance, and the decision-making process, all of which most likely affect treatment approach, surgical performance, and survival. Second, while this study population covers diverse areas of hospitals in Japan, not all hospitals in Japan participated, resulting in a potential selection bias. However, as described earlier, the sites that participated in the current study represent all the high-volume centers in Japan, which mitigates the possible selection bias. Third, due to the relatively long duration (10 years) of this study, there may have been changes in treatment methods, resulting in non-uniformity of treatment. A summary of these geographic disparities is shown in [supplemental Table S1](#app1-jcm-08-02081){ref-type="app"}.

5. Conclusions {#sec5-jcm-08-02081}
==============

In summary, the demographics and outcomes of vulvar cancer in Japan significantly changed during the study period: an increasing oldest-old population and a stage shift to more metastatic disease resulted in a cohort-level decrease in survival rates. The optimization of treatment strategies and screening methods will be useful to decrease mortality due to vulvar cancer in Japan.
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![Temporal trends of vulvar cancer in Japan from 2001 to 2010. Temporal trends (**A**) age-specific (annual percentage rate changes (APC) for age 60--79, −3.0, 95% confidence interval (CI) −4.2 to −1.7, *p* \< 0.001; and APC for ≥80, 6.1, 95% CI 1.6--10.8, *p* = 0.013), (**B**) histology type-specific, (**C**) stage-specific (APC for stage I disease, −2.6, 95% CI −4.9 to −0.2, *p* = 0.038; and APC for inguino-femoral nodal or distant metastasis, 4.9, 95% CI 1.2--8.7, *p* = 0.015), and (**D**) treatment type-specific (APC for surgery, −2.1, 95% CI −3.0 to −1.1, *p* \< 0.001; and APC for radiotherapy (RT), 2.6, 95% CI 0.3--4.9, *p* = 0.032).](jcm-08-02081-g001){#jcm-08-02081-f001}

![Cohort-level survival changes from 2001 to 2010. (**A**) Temporal trends for five-year progression-free survival (PFS), cause-specific survival (CSS), and overall survival (OS) rates from 2001 to 2010 for the Japan cohort, and (**B**) temporal trends for five-year CSS rates and proportion of women aged ≥80 years from 2001 to 2010 for the Japan and US cohorts.](jcm-08-02081-g002){#jcm-08-02081-f002}

jcm-08-02081-t001_Table 1

###### 

Patient demographics (*N* = 1061). SCC: squamous cell carcinoma, BCC: basal cell carcinoma, CCRT: concurrent chemoradiotherapy.

  Characteristics                       Number (%)
  ------------------------------------- --------------------
  No.                                   *N* = 1061
  Age                                   72 (IQR 62--79)
  \<60                                  222 (20.9%)
  60--79                                582 (54.9%)
  ≥80                                   257 (24.2%)
  Year                                  
  2001--2004                            336 (31.7%)
  2005--2007                            313 (29.5%)
  2008--2010                            412 (38.8%)
  Histology                             
  SCC                                   768 (72.4%)
  Paget                                 152 (14.3%)
  Adenocarcinoma                        59 (5.6%)
  BCC                                   45 (4.2%)
  Others                                37 (3.5%)
  Stage                                 
  IA                                    135 (12.7%)
  IB                                    262 (24.7%)
  II                                    249 (23.5%)
  IIIA                                  118 (11.1%)
  IIIB                                  104 (9.8%)
  IIIC                                  25 (2.4%)
  IIINOS                                4 (0.4%)
  IVA                                   68 (6.4%)
  IVB                                   96 (9.0%)
  Tumor size (cm)                       3.5 (IQR 2.4--5.3)
  ≤2.0                                  198 (18.7%)
  2.1--4.0                              362 (34.1%)
  4.1--6.0                              179 (16.9%)
  6.1--8.0                              84 (7.9%)
  8.1--10.0                             52 (4.9%)
  \>10.0                                23 (2.2%)
  Unknown                               163 (15.4%)
  Surgical treatment                    
  No                                    261 (24.6%)
  Yes                                   800 (75.4%)
  Vulva surgery type \*                 
  Simple vulvectomy                     227 (28.4%)
  Radical vulvectomy                    273 (34.1%)
  Partial vulvectomy                    297 (37.1%)
  Unknown                               3 (0.4%)
  Vulva reconstruction type \*          
  None                                  538 (67.3%)
  Cutaneous flap                        173 (21.6%)
  Partial skin graft                    55 (6.9%)
  Myocutaneous flap                     31 (3.9%)
  Unknown                               3 (0.4%)
  Surgical margin status (cm) \*        
  \>2                                   110 (13.8%)
  1--2                                  113 (14.1%)
  \<1                                   257 (32.1%)
  Involved                              179 (22.4%)
  Unknown                               141 (17.6%)
  Inguino-femoral lymphadenectomy \*    
  Not performed                         301 (37.6%)
  Performed                             494 (61.8%)
  Unknown                               5 (0.6%)
  Sentinel lymph node evaluation \*\*   
  Not performed                         451 (91.3%)
  Performed                             41 (3.9%)
  Unknown                               3 (0.6%)
  Lymph node metastasis \*\*\*          
  No metastasis                         489 (64.9%)
  Single metastasis                     98 (13.0%)
  Multiple metastases                   167 (22.1%)
  Perioperative complication \*         
  None                                  694 (87.0%)
  Yes                                   100 (12.5%)
  Unknown                               4 (0.5%)
  Lymphatic complication \*\*           
  No                                    473 (95.7%)
  Yes                                   20 (4.0%)
  Unknown                               1 (0.2%)
  Vulvar site complication \*           
  No                                    718 (89.8%)
  Yes                                   78 (9.8%)
  Unknown                               4 (0.5%)
  Radiotherapy                          
  No                                    643 (60.6%)
  Adjuvant                              168 (15.8%)
  Neoadjuvant                           19 (1.8%)
  Definitive                            194 (18.3%)
  Palliative                            29 (2.7%)
  Unknown                               8 (0.7%)
  CCRT ^§^                              
  No                                    306 (74.6%)
  Yes                                   103 (25.1%)
  Unknown                               1 (0.2%)
  Systemic chemotherapy                 
  No                                    818 (77.1%)
  Yes                                   152 (14.3%)
  Unknown                               91 (8.6%)

Number (%) or median (IQR) is shown. \* among surgery cases. \*\* among lymphadenectomy cases. \*\*\* among assessed cases including non-vulvar surgery cases. ^§^ Among radiotherapy cases. Abbreviations: IQR, interquartile range; SCC, squamous cell carcinoma; BCC, basal cell carcinoma; and CCRT, concurrent chemoradiotherapy.

jcm-08-02081-t002_Table 2

###### 

Age-specific clinico-pathological characteristics (*N* = 1061).

  Characteristics                       \<60          60--79        ≥80           *p*-Value
  ------------------------------------- ------------- ------------- ------------- -----------
  Year                                                                            0.010
  2001--2004                            75 (33.8%)    201 (34.5%)   60 (23.3%)    
  2005--2008                            87 (39.2%)    239 (41.1%)   111 (43.2%)   
  2009--2011                            60 (27.0%)    142 (24.4%)   86 (33.5%)    
  Histology                                                                       \<0.001
  SCC                                   147 (66.2%)   411 (70.6%)   210 (81.7%)   
  Paget                                 18 (8.1%)     33 (5.7%)     8 (3.1%)      
  Adenocarcinoma                        9 (4.1%)      28 (4.8%)     8 (3.1%)      
  BCC                                   20 (9.0%)     13 (2.2%)     4 (1.6%)      
  Others                                28 (12.6%)    97 (16.7%)    27 (10.5%)    
  Stage                                                                           0.432
  I                                     97 (43.7%)    212 (36.4%)   88 (34.2%)    
  II                                    47 (21.2%)    134 (23.0%)   68 (26.5%)    
  III                                   47 (21.2%)    143 (24.6%)   61 (23.7%)    
  IV                                    31 (14.0%)    93 (16.0%)    40 (15.6%)    
  Tumor size (cm)                                                                 0.703
  ≤4.0                                  125 (56.3%)   306 (52.6%)   129 (50.2%)   
  \>4.0                                 68 (30.6%)    184 (31.6%)   86 (33.5%)    
  Unknown                               29 (13.1%)    92 (15.8%)    42 (16.3%)    
  Surgical treatment                                                              \<0.001
  No                                    18 (8.1%)     130 (22.3%)   113 (44.0%)   
  Yes                                   204 (91.9%)   452 (77.7%)   144 (56.0%)   
  Vulva surgery type \*                                                           \<0.001
  Simple vulvectomy                     50 (24.6%)    137 (30.4%)   40 (27.8%)    
  Radical vulvectomy                    76 (37.4%)    175 (38.9%)   22 (15.3%)    
  Partial vulvectomy                    77 (37.9%)    138 (30.7%)   82 (56.9%)    
  Vulva reconstruction type \*                                                    0.007
  No                                    130 (64.0%)   295 (65.6%)   113 (78.5%)   
  Yes                                   73 (36.0%)    155 (34.4%)   31 (21.5%)    
  Surgical margin status (cm) \*                                                  0.027
  \>2                                   35 (20.1%)    67 (18.2%)    8 (6.8%)      
  1--2                                  34 (19.5%)    58 (15.8%)    21 (17.9%)    
  \<1                                   55 (31.6%)    148 (40.2%)   54 (46.2%)    
  Involved                              50 (28.7%)    95 (25.8%)    34 (29.1%)    
  Inguino-femoral lymphadenectomy \*                                              \<0.001
  Not performed                         70 (34.7%)    150 (33.4%)   81 (56.3%)    
  Performed                             132 (65.3%)   299 (66.6%)   63 (43.8%)    
  Sentinel lymph node evaluation \*\*                                             0.498
  Not performed                         116 (89.2%)   277 (92.6%)   58 (92.1%)    
  Performed                             14 (10.8%)    22 (7.4%)     5 (7.9%)      
  Lymph node metastasis \*\*\*                                                    0.774
  No metastasis                         106 (63.9%)   279 (65.8%)   104 (63.4%)   
  Single metastasis                     19 (11.4%)    58 (13.7%)    21 (12.8%)    
  Multiple metastases                   41 (24.7%)    87 (20.5%)    39 (23.8%)    
  Perioperative complication \*                                                   0.845
  None                                  176 (87.1%)   392 (87.1%)   128 (88.9%)   
  Yes                                   26 (12.9%)    58 (12.9%)    16 (11.1%)    
  Lymphatic complication \*\*                                                     0.190
  No                                    128 (97.7%)   283 (94.6%)   62 (98.4%)    
  Yes                                   3 (2.3%)      16 (5.4%)     1 (1.6%)      
  Vulvar site complication \*                                                     0.484
  No                                    178 (88.1%)   408 (90.7%)   132 (91.7%)   
  Yes                                   24 (11.9%)    42 (9.3%)     12 (8.3%)     
  Radiotherapy                                                                    \<0.001
  No                                    146 (66.4%)   360 (62.2%)   137 (53.9%)   
  Adjuvant                              46 (20.9%)    101 (17.4%)   21 (8.3%)     
  Neoadjuvant                           13 (5.9%)     4 (0.7%)      2 (0.8%)      
  Definitive                            14 (6.4%)     101 (17.4%)   79 (31.1%)    
  Palliative                            1 (0.5%)      13 (2.2%)     15 (5.9%)     
  CCRT ^§^                                                                        \<0.001
  No                                    40 (54.8%)    157 (71.7%)   109 (93.2%)   
  Yes                                   33 (45.2%)    62 (28.3%)    8 (6.8%)      
  Chemotherapy                                                                    \<0.001
  No                                    156 (70.3%)   440 (75.6%)   222 (86.4%)   
  Yes                                   47 (21.2%)    93 (16.0%)    12 (4.7%)     
  Unknown                               19 (8.6%)     49 (8.4%)     23 (8.9%)     

Number (percentage per column) is shown. Chi-square test for *p*-value. Significant *p*-values are emboldened; \* among surgery cases; \*\* among lymphadenectomy cases; \*\*\* among assessed cases including non-vulvar surgery cases; ^§^ among radiotherapy cases.
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###### 

Clinico-pathological characteristics of stage I disease (age-stratified).

  Characteristics                                  \<60         60--79        ≥80          *p*-Value
  ------------------------------------------------ ------------ ------------- ------------ -----------
  Year                                                                                     0.083
  2001--2004                                       30 (30.9%)   84 (39.6%)    21 (23.9%)   
  2005--2008                                       39 (40.2%)   83 (39.2%)    42 (47.7%)   
  2009--2011                                       28 (28.9%)   45 (21.2%)    25 (28.4%)   
  Histology                                                                                0.022
  SCC                                              57 (58.8%)   118 (55.7%)   64 (72.7%)   
  Non-SCC                                          40 (41.2%)   94 (44.3%)    24 (27.3%)   
  Stage                                                                                    0.085
  IA                                               39 (40.2%)   74 (34.9%)    22 (25.0%)   
  IB                                               58 (59.8%)   138 (65.1%)   66 (75.0%)   
  Tumor size (cm)                                                                          0.593
  ≤4.0                                             62 (77.5%)   141 (79.2%)   55 (73.3%)   
  \>4.0                                            18 (22.5%)   37 (20.8%)    20 (26.7%)   
  Surgical treatment                                                                       \<0.001
  No                                               0            11 (5.2%)     22 (25.0%)   
  Yes                                              97 (100%)    201 (94.8%)   66 (75.0%)   
  Vulva surgery type \*                                                                    0.003
  Simple vulvectomy                                30 (31.3%)   75 (37.5%)    21 (31.8%)   
  Radical vulvectomy                               18 (18.8%)   42 (21.0%)    1 (1.5%)     
  Partial vulvectomy                               48 (50.0%)   83 (41.5%)    44 (66.7%)   
  Vulva reconstruction type \*                                                             0.016
  No                                               72 (75.0%)   144 (72.0%)   59 (89.4%)   
  Yes                                              24 (25.0%)   56 (28.0%)    7 (10.6%)    
  Surgical margin status (cm) \*                                                           0.152
  ≥1                                               34 (41.0%)   49 (31.4%)    14 (25.9%)   
  \<1                                              49 (59.0%)   107 (68.6%)   40 (74.1%)   
  Inguino-femoral lymphadenectomy (stage IB) \*                                            0.003
  Not performed                                    27 (47.4%)   60 (46.9%)    36 (75.0%)   
  Performed                                        30 (52.6%)   68 (53.1%)    12 (25.0%)   
  Sentinel lymph node evaluation (stage IB) \*\*                                           0.468
  Not performed                                    24 (80.0%)   60 (88.2%)    11 (91.7%)   
  Performed                                        6 (20.0%)    8 (11.8%)     1 (8.3%)     
  Perioperative complication \*                                                            0.819
  None                                             89 (92.7%)   181 (90.5%)   60 (90.9%)   
  Yes                                              7 (7.3%)     19 (9.5%)     6 (9.1%)     
  Radiotherapy                                                                             \<0.001
  No                                               88 (90.7%)   189 (89.6%)   70 (80.5%)   
  Adjuvant                                         9 (9.3%)     12 (5.7%)     2 (2.3%)     
  Definitive                                       0            10 (4.7%)     14 (16.1%)   
  Palliative                                       0            0             1 (1.1%)     
  CCRT ^§^                                                                                 0.407
  No                                               8 (88.9%)    20 (90.9%)    17 (100%)    
  Yes                                              1 (11.1%)    2 (9.1%)      0            
  Chemotherapy                                                                             0.002
  No                                               76 (78.4%)   181 (85.4%)   79 (89.8%)   
  Yes                                              11 (11.3%)   6 (2.8%)      0            
  Unknown                                          10 (10.3%)   25 (11.8%)    9 (10.2%)    

Number (percentage per column) is shown. Chi-square test for *p*-value. Significant *p*-values are emboldened; \* among surgery cases; \*\* among lymphadenectomy cases; \*\*\* among assessed cases including non-vulvar surgery cases; ^§^ among radiotherapy cases.
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###### 

Multivariable models for age and survival outcomes.

                                  Whole Cohort   SCC                    Stage I   Surgery                                                          
  -------- ---------------------- -------------- ---------------------- --------- ----------------------- ------- ---------------------- --------- --
  PFS      \<60                   1                                     1                                 1                              1         
  60--79   1.436 (1.100--1.874)   0.008          1.666 (1.194--2.323)   0.003     2.046 (1.188--3.523)    0.010   1.409 (1.054--1.884)   0.021     
  ≥80      1.586 (1.139--2.209)   0.006          1.705 (1.153--2.521)   0.007     2.321 (1.139--4.732)    0.020   2.096 (1.424--3.086)   \<0.001   
  CSS      \<60                   1                                     1         0.091 \*                1                              1         
  60--79   1.347 (0.966--1.877)   0.079          1.440 (0.970--2.137)   0.070     2.089 (0.730--5.979)    0.170   1.433 (0.982--2.119)   0.062     
  ≥80      1.546 (1.033--2.313)   0.034          1.650 (1.046--2.601)   0.031     3.269 (0.934--11.438)   0.064   2.289 (1.340--3.909)   0.002     
  OS       \<60                   1                                     1                                 1                              1         
  60--79   1.513 (1.108--2.068)   0.009          1.540 (1.063--2.230)   0.022     1.754 (0.812--3.787)    0.152   1.596 (1.117--2.280)   0.010     
  ≥80      2.172 (1.509--3.126)   \<0.001        2.319 (1.536--3.500)   \<0.001   2.923 (1.171--7.292)    0.022   3.230 (2.031--5.137)   \<0.001   

Cox proportional hazard regression models for multivariable analysis. Significant *p*-values are emboldened. The association of age and survival outcome was adjusted for stage (I, II, III, or IV), histology (SCC versus non-SCC), tumor size (≤4.0 versus \>4.0 cm), surgery (yes versus no), radiotherapy (yes versus no), systemic chemotherapy (yes versus no), and year of diagnosis (continuous). HR: hazard ratio. \* among surgery cases.

[^1]: Abstract of the study was presented at the 2019 Congress Meeting for European Society for Medical Oncology, Barcelona, Spain, 27 September--1 October 2019.

[^2]: Authors contributed equally to the work.
